Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
SAN DIEGO, Aug. 15, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), today announced that the Irish Medicines Board and the Netherlands' Medicines Evaluations Board have each granted national phase approvals to Vitaros®, indicated for the treatment of patients with erectile dysfunction ("ED"). The Company has now received a total of four national phase approvals for Vitaros® including Ireland, the Netherlands, Sweden and the United Kingdom ("UK").
Help employers find you! Check out all the jobs and post your resume.
SAN DIEGO, Aug. 15, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), today announced that the Irish Medicines Board and the Netherlands' Medicines Evaluations Board have each granted national phase approvals to Vitaros®, indicated for the treatment of patients with erectile dysfunction ("ED"). The Company has now received a total of four national phase approvals for Vitaros® including Ireland, the Netherlands, Sweden and the United Kingdom ("UK").
Help employers find you! Check out all the jobs and post your resume.
